CRIS Current Research Information System

PANTANI, LUCIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 5.201
NA - Nord America 4.538
EU - Europa 3.014
AF - Africa 348
SA - Sud America 280
OC - Oceania 16
Continente sconosciuto - Info sul continente non disponibili 2
Totale 13.399
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.455
VN - Vietnam 1.690
CN - Cina 1.273
SG - Singapore 1.214
IT - Italia 833
GB - Regno Unito 499
DE - Germania 354
SE - Svezia 337
HK - Hong Kong 281
BR - Brasile 199
IN - India 192
FR - Francia 189
NL - Olanda 165
KR - Corea 159
RU - Federazione Russa 133
CI - Costa d'Avorio 131
IE - Irlanda 110
FI - Finlandia 94
BD - Bangladesh 86
JP - Giappone 67
ZA - Sudafrica 66
TG - Togo 60
SC - Seychelles 57
UA - Ucraina 57
PH - Filippine 46
CA - Canada 43
AR - Argentina 37
AT - Austria 36
EE - Estonia 33
BG - Bulgaria 32
CH - Svizzera 30
TH - Thailandia 28
BE - Belgio 26
MX - Messico 25
JO - Giordania 23
PL - Polonia 23
ES - Italia 19
ID - Indonesia 18
TW - Taiwan 18
IQ - Iraq 17
NG - Nigeria 15
TR - Turchia 15
AU - Australia 14
EC - Ecuador 14
IR - Iran 12
SA - Arabia Saudita 12
CZ - Repubblica Ceca 11
CL - Cile 10
CO - Colombia 7
MY - Malesia 7
UZ - Uzbekistan 7
PK - Pakistan 6
EG - Egitto 5
GT - Guatemala 5
LB - Libano 5
RO - Romania 5
DZ - Algeria 4
GR - Grecia 4
LT - Lituania 4
NP - Nepal 4
PT - Portogallo 4
VE - Venezuela 4
KZ - Kazakistan 3
PE - Perù 3
PY - Paraguay 3
RS - Serbia 3
TN - Tunisia 3
AL - Albania 2
AZ - Azerbaigian 2
CY - Cipro 2
GE - Georgia 2
GH - Ghana 2
HU - Ungheria 2
IL - Israele 2
KH - Cambogia 2
NO - Norvegia 2
OM - Oman 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AO - Angola 1
BO - Bolivia 1
BS - Bahamas 1
BY - Bielorussia 1
CR - Costa Rica 1
CW - ???statistics.table.value.countryCode.CW??? 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
HR - Croazia 1
JM - Giamaica 1
KE - Kenya 1
KG - Kirghizistan 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LC - Santa Lucia 1
LU - Lussemburgo 1
LV - Lettonia 1
MA - Marocco 1
MK - Macedonia 1
Totale 13.389
Salva come PNG Salva come JPEG
Città #
Singapore 846
Ashburn 604
Chandler 417
Ho Chi Minh City 404
Southend 398
Fairfield 331
Hefei 331
Hanoi 326
Hong Kong 270
Bologna 244
San Jose 231
Woodbridge 163
Beijing 153
Seoul 150
Ann Arbor 148
Dallas 148
Seattle 145
Wilmington 139
Houston 137
Dong Ket 136
Abidjan 131
Cambridge 115
New York 113
Dublin 110
Santa Clara 110
Princeton 109
Boardman 89
Los Angeles 84
Lauterbourg 76
Helsinki 68
Lomé 60
Haiphong 59
Milan 59
Council Bluffs 54
Tokyo 54
Nanjing 46
Bremen 45
Munich 41
Hyderabad 40
Da Nang 39
Frankfurt am Main 39
Westminster 38
São Paulo 36
Padova 33
Sofia 32
Turin 31
Jinan 30
Bengaluru 29
Buffalo 29
Jacksonville 28
Berlin 27
Redmond 27
Brussels 25
Guangzhou 25
Redondo Beach 25
San Diego 24
Vienna 24
Amman 23
Changsha 23
Chicago 23
Shenyang 23
Amsterdam 22
Fabriano 22
Redwood City 22
Saint Petersburg 21
Bern 20
Can Tho 20
Nuremberg 20
Johannesburg 19
Biên Hòa 18
Florence 18
Lappeenranta 18
Rome 18
Ha Long 17
Quận Bình Thạnh 17
Zhengzhou 17
Nanchang 16
Tianjin 16
London 15
Shanghai 15
Thái Nguyên 15
Abeokuta 14
Atlanta 14
Hải Dương 14
Medford 14
Falkenstein 13
Ninh Bình 13
Toronto 13
Warsaw 13
Washington 13
Wuhan 13
Hebei 12
Bắc Ninh 11
Charlotte 11
Dhaka 11
Falls Church 11
Jakarta 11
Naples 11
Orem 11
Paris 11
Totale 8.417
Salva come PNG Salva come JPEG
Nome #
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma 711
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease 349
Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment 270
Peripheral neuropathy induced by subcutaneous bortezomib-based induction therapy for newly diagnosed multiple myeloma. 249
Positron emission tomography with computed tomography-based diagnosis of massive extramedullary progression in a patient with high-risk multiple myeloma. 247
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes 236
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD) 233
Treatment optimization for Multiple Myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in an in vitro and ex-vivo model 230
A 41-gene signature predicts complete response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) as induction therapy prior to autologous stem-cell transplantation (ASCT) in multiple myeloma (MM). 222
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. 219
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. 215
Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma 211
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study 211
Identification of a Maturation Plasma Cell Index through a Highly Sensitive Droplet Digital PCR Assay Gene Expression Signature Validation in Newly Diagnosed Multiple Myeloma Patients 210
Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma 210
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma 209
Clinical Presentation and Long‐Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study 208
Circulating Multiple Myeloma Cells (CMMCs) as Prognostic and Predictive Markers in Multiple Myeloma and Smouldering MM Patients 205
HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment 203
Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma 202
Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma 202
Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study 201
Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens 199
Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis 198
Diagnostic Innovations: Advances in imaging techniques for diagnosis and follow-up of multiple myeloma 190
Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma 189
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases 189
Thalidomide maintenance in multiple myeloma: certainties and controversies. 184
Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma 184
Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency. 180
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma. 179
The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma 179
High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis 178
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 178
PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma 177
Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma. 175
Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents 175
A 41-Gene Signature Predicts Complete Response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) As Induction Therapy Prior to Autologous Stem-Cell Transplantation (ASCT) in Multiple Myeloma (MM) 174
HIF 1 Alpha: A Suitable Target for Multiple Myeloma 174
Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy 172
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma 171
Unique molecular assay (UMA): a next-generation sequencing targeted panel for efficient and comprehensive genomic profiling and risk stratification of multiple myeloma 166
High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53 166
Early Light Chains Removal and Albumin Levels with a Double Filter-Based Extracorporeal Treatment for Acute Myeloma Kidney 164
Genomic characterization of the putative myeloma stem cells clone reveals alterations possibly correlated with the origin of disease. 163
Long-term follow-up after autologous stem cell transplantation for light- and heavy-chain deposition disease. 158
Gene expression analysis of newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted p5 155
High CNA level and over-expression of genes involved in response mechanisms to genotoxic stress characterize newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted TP53 154
OAB-006: A novel algorithm to identify, characterize and define the prognostic impact of complex catastrophic events in Multiple Myeloma 153
Single-Cell DNA Sequencing Reveals an Evolutionary Pattern of CHIP in Transplant Eligible Multiple Myeloma Patients 153
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 151
Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features 150
SIRT Regulates the Molecular Interaction Between c-MYC and HIF-1α in Multiple Myeloma 145
High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients 141
VarianThinker: a classification method to confidently approach the mutation heterogeneity in Multiple Myeloma 141
SIRT regulates the molecular interaction between c-MYC and HIF-1 alpha in multiple myeloma 135
Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. 135
Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation 133
Impact Of p53 Impaired Function On Outcomes Of Multiple Myeloma Patients Carrying Deleted TP53 and/Or Amplified MDM4 132
Rare, but complex chromosomal rearrangements, defined "Chromoanagenesis”, caused by single-step or stepwise catastrophic genomic events, significantly impact on Multiple Myeloma patients 131
Emerging and current treatment combinations for transplant-ineligible multiple myeloma patients 129
The Value of 18F-FDG PET/CT after Autologous Stem Cell Transplantation (ASCT) in Patients Affected by Multiple Myeloma (MM): Experience With 77 Patients 121
Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma 119
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients 118
Interference of daratumumab and efficacy of plerixafor on haematopoietic stem cell collection in Multiple Myeloma 117
Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients—A Systematic Review 117
Case Report: Uncommon co-occurrence of different renal histopathological entities in a patient with multiple myeloma and lymphoplasmacytic lymphoma 109
Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study 100
null 98
Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma 97
Proteasome inhibitors: Bortezomib in multiple myeloma 93
OAB-057: Temporal-weight estimation of the copy number alterations of of 1384 Multiple Myeloma patients defines an ancestrality index impacting patients survival 92
Bispecific Antibodies and CAR T in Multiple Myeloma: Appropriate Selection of Patients and Sequencing 88
Abstract 2700: Negative selective pressure exerted by maintenance therapy promotes the extinction of sub-clones carrying high-risk lesions in multiple myeloma 87
Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies? 84
Ten-year experience on home care for patients with plasma cell disorders: bringing optimal therapy home 81
IMPLEMENTATION OF NEXT GENERATION SEQUENCING AS BEST TOOL FOR ROUTINE EVALUATION OF MINIMAL RESIDUAL DISEASE IN THE DAILY PRACTICE OF MULTIPLE MYELOMA PATIENTS 79
A multicenter observational retrospective study of second-line treatment with daratumumab–bortezomib–dexamethasone (DaraVd) in multiple myeloma patients refractory to lenalidomide 70
The road to cure in multiple myeloma: Incorporation of novel agents into autologous stem cell transplantation 64
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial 58
Totale 13.645
Salva come PNG Salva come JPEG
Categoria #
all - tutte 36.765
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.765
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021308 0 0 0 0 0 0 0 0 0 0 0 308
2021/20221.192 136 52 60 93 89 51 27 82 48 136 208 210
2022/20231.597 141 222 63 262 108 134 46 97 269 54 121 80
2023/2024603 41 83 34 51 47 152 27 83 13 19 31 22
2024/20251.973 113 193 172 173 207 78 144 68 51 228 177 369
2025/20265.842 538 1.031 461 455 516 281 504 175 1.063 406 237 175
Totale 13.645